Peter Voser - Roche Holding Non-Executive Director
| RHHBY Stock | USD 30.05 0.03 0.1% |
Director
Mr. Peter R. Voser is no longer a NonExecutive Independent Director at Roche Holding Ltd effective June 30th, 2019. He is Member of the Remuneration Committee at the Company. He started his career in 1982 by joining the Royal Dutch Shell. He held there various finance and business roles in Switzerland, the United Kingdom, Argentina and Chile. In 1997 he became Group Chief Internal Auditor at the company and in 1999 he was appointed Chief Financial Officer of Shell Europe Oil Products. In 2001 he became CFO of the Global Oil Products Business and Member of the Oil Products Executive Committee. Between 2002 and 2004, Mr. Voser acted as CFO and an Executive Committee Member of the Asea Brown Boveri Group of Companies. From 2004 and 2009 he held the position of Chief Financial Officer and an Executive Director of Royal Dutch Shell. Since 2009 he was active as Chief Executive Officer of Royal Dutch Shell and since 2010, he has acted as Director of Catalyst. He studied Business Administration at Zuercher Hochschule fuer angewandte Wissenschaften, ZHAW .
| Age | 59 |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stacey Cartwright | GlaxoSmithKline PLC ADR | 51 | |
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Michel Demare | AstraZeneca PLC ADR | 62 | |
| Kathy Warden | Merck Company | 49 | |
| Frans Houten | Novartis AG ADR | 61 | |
| Carla Hills | Gilead Sciences | 80 | |
| Philip Hampton | GlaxoSmithKline PLC ADR | 64 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
| Paul Rothman | Merck Company | 63 | |
| John Madigan | Gilead Sciences | 77 | |
| Harish Manwani | Gilead Sciences | 64 | |
| Manvinder Banga | GlaxoSmithKline PLC ADR | 62 | |
| William Harrison | Merck Company | 70 | |
| Leslie Brun | Merck Company | 68 | |
| Jacqueline Barton | Gilead Sciences | 65 | |
| Urs Rohner | GlaxoSmithKline PLC ADR | 60 | |
| Togo West | Bristol Myers Squibb | 72 | |
| Richard Whitley | Gilead Sciences | 72 | |
| Simon Moroney | Novartis AG ADR | 62 | |
| Christian Mulliez | Sanofi ADR | 57 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Head of Group HR | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, General Counsel and Corporate Secretary | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, COO of Pharmaceuticals division | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding Ltd. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |